Ligand Pharmaceuticals Incorporated
LGND · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -1.01 | -0.34 | -0.05 |
| FCF Yield | 0.00% | 0.71% | -1.27% | 1.37% |
| EV / EBITDA | 51.01 | 99.83 | -48.69 | -66.28 |
| Quality | ||||
| ROIC | 4.36% | 0.41% | -3.61% | -0.84% |
| Gross Margin | -59.49% | 76.56% | 89.30% | 93.37% |
| Cash Conversion Ratio | 0.11 | 3.26 | 0.60 | -0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | 24.48% | 6.20% | 0.21% | -1.13% |
| Free Cash Flow Growth | 0.00% | 160.74% | -192.43% | 24.54% |
| Safety | ||||
| Net Debt / EBITDA | -3.39 | -2.91 | 1.07 | 2.20 |
| Interest Coverage | -27.19 | 7.32 | -41.77 | -10.91 |
| Efficiency | ||||
| Inventory Turnover | 2.04 | 0.72 | 0.41 | 0.20 |
| Cash Conversion Cycle | 88.99 | -5.53 | 204.71 | 370.97 |